ANASTROZOLOS 1 - Pharmacom Labs

Anastrozole was developed by “Zeneca Pharmaceuticals” and eventually approved in 1995, is a third generation aromatase blocker that improved breast cancer therapy. By blocking the enzyme which is  responsible for producing estrogen in human bodies, it became a very  effective solution for hormone-sensitive cancers in postmenopausal women. Its selective action in lowering estrogen levels positioned it as a vital alternative to drugs like tamoxifen, helping to improve treatment outcomes.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about ANASTROZOLOS 1 by Pharmacom Labs, consult with your doctor or healthcare professional.